Insider Selling: Cellebrite DI (NASDAQ:CLBT) CEO Sells $1,626,242.88 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CEO Thomas Hogan sold 103,188 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the completion of the sale, the chief executive officer owned 590,777 shares in the company, valued at approximately $9,310,645.52. This trade represents a 14.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $16.13 on Friday. The company has a market capitalization of $4.02 billion, a price-to-earnings ratio of 57.61, a price-to-earnings-growth ratio of 2.05 and a beta of 1.17. Cellebrite DI Ltd. has a one year low of $11.02 and a one year high of $19.98. The stock has a 50-day simple moving average of $13.70 and a 200 day simple moving average of $14.52.

Hedge Funds Weigh In On Cellebrite DI

Several institutional investors have recently modified their holdings of the company. Portolan Capital Management LLC grew its holdings in Cellebrite DI by 139.1% in the 3rd quarter. Portolan Capital Management LLC now owns 2,419,662 shares of the company’s stock worth $44,836,000 after buying an additional 1,407,818 shares in the last quarter. Capital Research Global Investors raised its stake in Cellebrite DI by 42.3% during the 3rd quarter. Capital Research Global Investors now owns 2,425,736 shares of the company’s stock valued at $44,949,000 after acquiring an additional 721,154 shares in the last quarter. Granahan Investment Management LLC raised its stake in Cellebrite DI by 1,108.5% during the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after acquiring an additional 2,411,726 shares in the last quarter. Thematics Asset Management boosted its position in Cellebrite DI by 22.6% during the 3rd quarter. Thematics Asset Management now owns 1,066,850 shares of the company’s stock worth $19,769,000 after acquiring an additional 196,924 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in Cellebrite DI by 28.6% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,350,000 shares of the company’s stock worth $24,341,000 after acquiring an additional 300,000 shares during the period. Institutional investors own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. DA Davidson initiated coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.